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ABSTRACT
Hypotheses concerning paradoxical, psychostimulant-related side effects experienced by
ADHD children were examined in the context of a double-blind, placebo-controlled, within
subject (crossover) experimental design. Results revealed that behavioral and physical
complaints were significantly higher under baseline relative to placebo and the four
methylphenidate (MPH) conditions (5-mg, 10-mg, 15-mg, 20-mg) across three symptom
categories: ADHD core/secondary symptoms, symptoms common to all children, and symptoms
highly specific to MPH. No significant differences were found among active drug conditions.
Implications of these findings for assessing and monitoring potential treatment emergent
symptoms in children are discussed.
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW
Attention Deficit Hyperactivity Disorder (ADHD) is a complex and chronic disorder of
brain, behavior, and development whose behavioral and cognitive consequences pervade
multiple areas of functioning. Core features of the disorder involve difficulties with attention,
impulsiveness, and hyperactivity (DSM-IV, 1994), and are hypothesized to affect behavioral and
cognitive functioning to the extent that the latter are dependent upon the former for successful
execution (Rapport, Chung, Shore, & Issacs, 2001).
Treatment of attention deficits traditionally involves using behavior or pharmacological
therapy alone or in combination (for reviews, see Conners, Epstein, & March, 2001; Jensen,
1999; Pelham et al., 1998; Swanson, McBurnett, Christian, & Wigal, 1995). Pharmacological
interventions (and particularly the psychostimulants), however, are generally considered more
cost effective and have the added benefit of affecting both behavioral and cognitive domains
throughout the day without the specific programming and oversight required by behavior therapy
(Douglas, Barr, O’Neil, & Britton, 1985; DuPaul & Eckert, 1997; Gittelman-Klein & Klein,
1976; MTA Cooperative Group, 1999). Methylphenidate (MPH) is by far the most commonly
prescribed pharmacological treatment for ADHD (Faraone, Biederman, & Roe, 2002; Grcevich,
Rowane, Marcellino, & Sullivan-Hurst, 2001; Jensen et al., 1999; Swanson & Volkow, 2002),
and its reputation is well deserved based on traditional benchmarks such as the breadth of
effectiveness and overall response rate among affected individuals.
Beneficial effects are observed across multiple domains of functioning based on direct
observations of children’s attention, behavior and academic performance (Barkley, 1977;
Cunningham, Seigel, & Offord, 1985; Douglas, Barr, O’Neil, & Britton, 1985; DuPaul &
1

Rapport, 1993; Rapport, Denney, DuPaul, & Gardner, 1994), parent and teacher ratings of social
deportment (DuPaul et al., 1993; Fischer & Newby, 1991; Musten, Firestone, Pisterman,
Bennett, & Mercer, 1997; MTA Cooperative Group, 1999), and objective performance indices
associated with a wide range of clinic-based neurocognitive tests, tasks, and paradigms (for
reviews, see Denney & Rapport, 2001; Losier, McGrath, & Klein, 1996; Rapport & Kelley,
1991). Peer relationships and interpersonal behavior (Barkley, Karlsson, Pollard, & Murphy,
1985; Cunningham, Seigel, & Offord, 1991; Cunningham et al., 1985; Humphries, Kinsbourne,
& Swanson, 1978; Smith et al., 1998; Whalen et al., 1989), and even performance during
extracurricular activities such as playing baseball (Pelham et al., 1990), may improve as a
function of treatment. Treatment response rates are remarkable and estimated to range between
50% and 96% depending on the stringency with which positive response is defined and the
nature of the targeted outcome variable (Barkley, 1997; Denney & Rapport, 2001). As with all
therapies, however, treatment emergent symptoms can and do occur.
Side effects associated with psychostimulant treatment are well documented in the literature
and most fall into one of three categories: cardiovascular effects (i.e., heart rate, blood pressure),
physical effects (i.e., weight and growth), and physical and behavioral complaints. Recent
reviews indicate that cardiovascular and physical effects associated with psychostimulant therapy
are usually transient, dose dependent, readily resolved by discontinuing therapy, and fail to
remain significant in long-term follow-up studies (Rapport & Moffitt, 2002). Investigations of
psychostimulant related physical and behavioral complaints, however, have generated renewed
interest owing to the paradoxical effects reported in recent, better-controlled studies. For
example, higher mean severity ratings of physical and behavioral complaints were reported by
teachers for children under placebo relative to children under low MPH doses (Barkley,
2

McMurray, Edelbrock, & Robbins, 1990; DuPaul, Anastopoulos, Kwasnick, Barkley, &
McMurray, 1996; Fischer & Newby, 1991). Parents also report that their children experience
fewer physical and behavioral complaints such as daydreaming, irritability, anxiety and nail
biting under MPH than placebo (Ahman et al., 1993).
Two hypotheses have been proposed to account for the paradoxical findings: (a) that adult
raters (parents, teachers) confuse some symptoms of the disorder such as daydreaming and
staring with drug-related side effects (Fine & Johnson, 1993; Firestone, Monteiro Munsten,
Pisterman, Mercer, & Bennett, 1998); and (b) that ratings under no medication conditions (i.e.,
baseline, placebo) reflect normal levels of physical and behavioral complaints for boys in
general, or boys with ADHD in particular, that may occur less frequently as a function of
treatment (Rapport, Moffitt, & Randall, 2002). Both hypotheses are possibly owing to the nonspecific nature of side effect rating scales. Most are designed to assess a wide range of possible
symptoms rather than emergent symptoms associated with a specific pharmacological regimen.
The rater confusion hypothesis can be addressed by examining the type of physical and
behavioral complaints reported under no-drug conditions, and changes from this state that occur
under placebo and active drug conditions. Treatment related decreases in only those physical and
behavioral complaints that mimic core or secondary features of ADHD (e.g., inattentiveness,
difficulty concentrating, staring, daydreaming), coupled with no change or a worsening of
complaints not typically associated with the disorder (e.g., cardiovascular, gastrointestinal, and
pseudoneurological symptoms) lends empirical support to the rater confusion hypothesis.
Juxtaposition of the psychostimulant emergent symptom literature with extant literature
concerning the occurrence of physical and behavioral complaints in samples of non-referred and
clinically diagnosed children is needed to examine the latter hypothesis.
3

The occurrence of physical and behavioral complaints in community samples of nonreferred children and adolescents is well documented. For example, nearly half of the 540
children and adolescents in a community sample attending 3rd through 12th grade reported at least
one physical symptom during the preceding two weeks (Garber, Walker, & Zeman, 1991), with
the highest frequency of complaints involving headaches (25%), low energy (23%), sore muscle
(21%), and abdominal discomfort (17%). Literature reviews confirm that headaches represent the
most commonly reported painful physical and behavioral symptom, and occur in 10% to 30% of
community samples of children on at least a weekly basis (Campo & Fritsch, 1994).
Epidemiological studies corroborate these findings, wherein 50% to 80% of children report some
type of headache within the past year (Barea, Tannhauser, & Rotta, 1996), and upwards to 15%
experience headaches of a migrainous nature (Abu-Arefeh & Russell, 1995). Recurrent
abdominal pain is also common (i.e., 10% to 25% of school-age children and adolescents), and
nearly 15% of children complain of daily fatigue (Apley, 1975; Garber et al., 1991; Linna, 1991).
Other physical and behavioral complaints commonly reported by children include
musculoskeletal pain, back pain, and dizziness (Campo & Fritsch, 1994).
Physical and behavioral complaints in children are not limited to Western culture (cf.
Belmaker, Espinoza, & Pogrund, 1985), and extant evidence suggests that the frequency and
type of physical and behavioral complaints vary with age and gender (Last, 1991). For example,
recurrent abdominal pain appears to be more common in early childhood, whereas headache,
limb pain, and polysymptomatic somatization in general increases with age (Achenbach, 1989).
Psychiatric disability confers additional risk for physical and behavioral complaints. Twenty
to 69% of children and adolescents with at least one psychiatric diagnosis experience physical
and behavioral complaints (Egger, Costelo, & Angold, 1999; Masi, Favilla, Millepiedi, & Mucci,
4

2000; Taylor, Szatmari, Boyle, & Offord, 1996), particularly children with anxiety disorders.
Children with panic disorder and separation anxiety are significantly more likely to complain of
physical and behavioral symptoms than children with other primary anxiety diagnoses or
depression (Last, 1991); however, physical and behavioral complaints are also prominent in
children with depression (Carlson & Kashani, 1998, Pine, 2002; Ryan, Puig-Antich, Ambrosini,
& Rabinovich, 1987). Children with externalizing disorder are also at greater risk than nonpsychiatric controls for physical and behavioral complaints. Boys with conduct disorder report
twice as many headaches as boys without the disorder, and ADHD is associated with more
frequent complaints of stomach aches (Egger et al., 1999), polydypsia, and polyuria (Mitchell,
Aman, Turbott, & Manku, 1987) relative to non-psychiatrically disabled children.
Collectively, the physical and behavioral complaint literature indicates that moderate to
elevated physical and behavioral complaints consisting of headache, low energy, sore muscles,
abdominal discomfort, daily fatigue, musculoskeletal pain, back pain, and dizziness are common
among children, and that a diagnosis of ADHD confers potentially additive risk for
stomachaches, polydipsia, and polyuria. These findings suggest that a substantial number of
physical and behavioral complaints attributed to medication in past studies may have been
confounded with high base rate occurrences of these behaviors in children with ADHD. This
hypothesis can be examined by comparing base rate occurrences of physical and behavioral
complaints with those reported under placebo and active medication conditions. A stable or
decreasing frequency of complaints under placebo and active medication conditions relative to
baseline levels supports the pre-existing/normal level complaints hypothesis.
Other types of emergent symptoms specific to MPH therapy (e.g., cardiovascular symptoms,
upset stomach, reduced appetite), other than those commonly reported by children or potentially
5

confused core and secondary symptoms of ADHD, may worsen as a function of increasing MPH
dose. These can be extracted from side effect rating scales and examined separately to determine
whether changes in frequency occur as a function of expectancy (placebo) or active drug over
and above base rate levels.
The purpose of the present study was to examine several factors that may account for
reported reductions in physical and behavioral complaints in children with ADHD as a function
of psychostimulant therapy. Rival hypotheses concerning paradoxical effects associated with
psychostimulant therapy and physical and behavioral complaint occurrence in children with
ADHD were examined using a large sample of children with ADHD, and evaluated in the
context of a double-blind, placebo-controlled, within subject (crossover) experimental design.
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CHAPTER TWO: METHODOLOGY

Participants
One hundred thirty-four children were screened for inclusion in the study based on referrals
from psychiatrists, pediatricians, and school personnel over a 5-year period. All children and
their parents participated in a detailed, semi-structured clinical interview with the clinic’s
supervising psychologist (M.D.R.). The interview was adapted from the Schedule for Affective
Disorders and Schizophrenia for School-Age Children (Kaufman et al., 1997) and reviewed
symptoms associated with disorders usually evident in childhood and adolescence as outlined in
the DSM-III (American Psychiatric Association, 1980). Children were required to meet the
following inclusion criteria: (1) an independent diagnosis by the child’s referring physician and
the Children’s Learning Clinic (CLC) clinical psychologist (M.D.R.) using DSM-III criteria for
ADDH; (2) a maternal report of a developmental history consistent with ADDH and problems in
at least 50% of the situations on Barkley’s (1990) Home Situations Questionnaire; (3) a maternal
rating of at least 2 standard deviations above the mean for the child’s age on the Werry-WeissPeters Activity Scale (Routh, Schroeder, & O’Tauma, 1974); (4) a teacher rating of at least 2
standard deviations above the mean on the Abbreviated Conners Teacher Rating Scale (ACTRS)
(Conners, 1990); and (b) absence of any gross neurological, sensory, or motor impairment as
determined by pediatric examination.
Sixty-five children (58 boys, 7 girls) met criteria and participated in the study after written
informed consent was obtained from their parent. Selected children were between 6 and 11 years
of age (mean age = 8.56) and fell within the average range of intelligence (mean = 102.8; SD =
7

10) based on the Peabody Picture Vocabulary Test–Revised, Form L (Dunn & Dunn, 1981). All
participants were Caucasian and from families of low to middle socioeconomic status
(Hollingshead, 1975). Eight had experienced brief trials of psychostimulant within the past 4
years.
All children were considered pervasively hyperactive as judged by clinical interview and
rating scale scores. A systematic review using current diagnostic nomenclature indicated that
each of the 65 children would currently be classified as meeting criteria defining ADHD
combined type, as detailed in the DSM-IV (American Psychiatric Association, 1994). The
clinical outcome of these children has been reported elsewhere (Rapport et al., 1994) and the
ADHD moniker will be used throughout this report.
Many of the children showed symptoms of but did not meet formal criteria for mood and
anxiety disorders. As a result, findings of this study may not generalize to children comorbid for
ADHD and anxiety or affective disorders. Comorbidity for oppositional defiant disorder was not
assessed because of the controversial nature of the disorder at the time the study was initiated.
All selected children were attending regular elementary school classrooms, although several
received concurrent special education services. Learning disabilities were not specifically
assessed.
Thirty-one of the 69 nonparticipating children met criteria and were enrolled in an
abbreviated placebo-controlled medication trial (5 to 15 mg of MPH) during the first year of the
clinic’s operation and are not reported here. Insufficient data were available for 2 children
because of school conflicts, and 1 child moved out of state before completing the study. Side
effect ratings were not obtained for the first 11 children participating in the 5-20 mg medication
trials because the procedure was implemented late in the second year of the clinic’s operation.
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The remaining 24 children scored within the established range for inclusion on the various rating
scales, but their developmental histories were inconsistent with DSM-III criteria (i.e., onset of
symptoms later than age 7 and/or duration less than 6 months). Fourteen of these children met
criteria for conduct disorder, seven showed symptoms of anxiety disorder (1 social phobia, 6
separation anxiety disorder), one had an eating disorder, and two were referred for neurological
evaluation because there was evidence of a seizure disorder.

Experimental Design and Procedures
Drug administration. A double-blind, placebo-controlled, within-subject (crossover)
experimental design was used in which ADHD children received a placebo and each of four
active MPH doses after baseline assessment. Order of dose administration was counterbalanced
and determined by random assignment such that an equal number of children received each dose
during a given week of the study. MPH was prescribed by each child’s physician in the
following doses: placebo, 5 mg (range = .10 to 0.26 mg/kg), 10 mg (range = 0.20 to 0.52 mg/kg),
15 mg (range = 0.29 to 0.79 mg/kg) and 20 mg (range = 0.39 to 1.1 mg/kg). Fixed doses were
used to reflect typical pediatric practice and because response to MPH is independent of body
mass (Rapport & Denney, 1997; Swanson, Cantwell, Lerner, & McBurnett, and Hanna, 1991).
MPH and placebo doses were packaged in colored gelatin capsules by the clinic’s pharmacist to
avoid detection of dose and taste. Capsules were sealed in individual, daily envelopes to help
control for accurate administration.
After baseline data collection (first week), parents were given 1 week’s medication in
predated envelopes at a single dose level (i.e., placebo, 5 mg, 10 mg, 15 mg, or 20 mg). Single
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morning doses (as opposed to twice per day) were administered to maintain experimental
control, as it was not possible to ensure that medication would be appropriately administered at
school at an established time during the day. This procedure continued until each child received
every dose for 6 consecutive days. All weekly dose changes occurred on Sundays (i.e., no
capsules were administered on Saturdays) to allow for “washout” and to control for possible
rebound effects. Parents were instructed to give their child a capsule each morning, one half hour
before breakfast. Both used and unused envelopes were returned on a weekly basis to control for
medication compliance. Medication was properly administered nearly 100% of the time.
“Makeup” observation days were scheduled in 4 cases when compliance was not obtained.

Procedures
Parents and children completed the Subjective Treatment Emergent Symptoms Scale
(STESS; Guy, 1976) during baseline, placebo, and each of the MPH conditions. The STESS was
initially devised for adult raters and consists of questions concerning the occurrence and severity
of a broad range of possible physical and behavioral complaints and emergent symptoms
associated with pharmacotherapy. A child version was created using the same items (exceptions
noted below), but reworded to ask children whether they had experienced a particular problem
within the past three days, and if so, the degree of severity using the original version's 4-point
response format (“not at all,” “just a little,” “pretty much,” “very much”). The original format of
the STESS included several potential physical and behavioral complaints that would be difficult
to interpret in terms of directionality, such as whether a child experienced problems with eating,
drinking, or bowel movements (i.e., it would be unclear whether the child was eating more or
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less, drinking more or less, or having more or fewer bowel movements). To reduce ambiguity,
these items were reworded to include a directional outcome (e.g., During the past three days did
you feel more thirsty?). The revised child version included a total of 63 questions.
Parents were asked to complete the scale during each weekly visit throughout the study. The
outcome reflected the physical and behavioral symptoms for the preceding week. Children were
administered the scale during each weekly visit by trained graduate research assistants who read
each item aloud to the child and recorded their verbal response. Graduate assistants were blind
concerning children’s medication status. Completed questionnaires reflected physical and
behavioral complaints experienced by children within the past three days and associated with a
single experimental condition (baseline, placebo, or one of the four MPH conditions).
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Table 1: Summary of symptoms included in STESS scale that may reflect Core/Secondary
symptoms of ADHD.
Parent
Clumsiness
Difficulty sitting still
Difficulty sleeping
Decreased sleep
Crying
Daydreaming
Difficulty with attention
More talkative
Difficulty with sports
Difficulty with parent relationships
Difficulty with peer relationships
Anger
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Table 2: Summary of most common symptoms found in the general population and in children
with ADHD
Parent

Child

Stomachaches

Stomachaches

Cramps

Cramps

Headaches

Headaches

Dizziness

Dizziness

Tiredness/fatigue

Tiredness/fatigue

Muscle aches

Muscle aches
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Table 3: STESS scale items considered emergent symptoms or true side effects
Parent

Child

Less Eating

Less Eating

More drinking

More drinking

Dry mouth

Dry mouth

----

More bowel movements

Constipation

Fewer bowel movements

---

Harder bowel movements

Diarrhea

Softer bowel movements

Nausea

Sick to stomach

----

Throw up

Bedwetting

More bedwetting

Polyurea

Polyurea

Decreased urine

Decreased urine

Painful urination

Painful urination

Skin itching

Skin itching

Rash

Rash

Light sensitivity

---

Difficulty with balance

---

Difficulty with speech

Difficulty with harder words
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Table 3 (continued)
Parent

Child

Shaky hands

More shaky

---

Harder to do things with hands

More bad dreams

More bad dreams

Difficult to please

---

More serious

---

Silliness

---

More energy

More energy

Less Energy

---

More withdrawn

---

Unhappy

Unhappy

Happiness

---

More repetitive behaviors

---

More self-harm behaviors

---

Feeling “worse”

Feeling “worse”

Note. Dashes indicate item was not included in the questionnaire.
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CHAPTER THREE: RESULTS
A three-tier data analytic strategy was used to examine the study’s two primary
hypotheses: (a) rater confusion (i.e., that adult raters confuse some features of ADHD with drug
related side effects); and (b) that baseline/placebo measures reflect normal levels of physical and
behavioral complaints for boys in general or children with ADHD in particular. Children and
parents completed the Subjective Treatment Emergent Symptoms Scale (STESS; Guy, 1976)
during baseline, placebo, and each of the MPH conditions. All data was grouped into the
following physical and behavioral complaint categories: (a) descriptions of physical and
behavioral complaints related to core and secondary features of ADHD (Ahman, et al., 1993;
Barkley et al., 1990; Beidel et al., 1991; DSM-IV, 1994) (see Table 1); (b) descriptions of
physical and behavioral complaints common to pediatric age children (Belmaker et al., 1985;
Campo et al., 1994; Garber et al., 1991), including those frequently reported by children with
ADHD not receiving psychostimulant therapy (Egger et al., 1999; Mitchell et al., 1987) (see
table 2); and (c) physical and behavioral complaints commonly reported in children receiving
MPH treatment (e.g., nausea/upset stomach, dry mouth, decreased appetite) (see Table 3).
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Tier I Analysis: Rater Confusion Hypothesis
Parent reports of physical and behavioral complaints in the symptom category that mimics
core/secondary features of ADHD were analyzed using a within subjects (parents) x 6
(conditions: baseline, placebo, 5 mg, 10 mg, 15 mg, 20 mg) repeated measures analysis of
variance (ANOVA). The analysis examines the hypothesis that adult raters confuse ADHD
core/secondary features as MPH side effects. A p-value of .05 was used to evaluate significance
for all analyses. The main effect for drug condition was significant [F (5, 640) = 16.34, p<.001].
Post hoc analysis using Tukey’s HSD revealed that parent endorsement of physical and
behavioral complaints that mimic secondary/core ADHD features under baseline were
significantly higher than complaints endorsed under placebo and all active medication conditions
(all p-values<.05). Significant differences were also found between placebo and the four MPH
conditions (all p-values<.05). No significant differences emerged among the four MPH doses
(see Figure 1).
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Figure 1: Mean severity ratings of physical and behavioral complaints in core and secondary
features of ADHD category endorsed by parents under baseline, placebo, and methylphenidate
conditions.
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Analysis of trend was performed to examine the shape of the relationship between parent ratings
of physical and behavioral complaints and MPH dose. Parent endorsements under baseline and
active medication conditions were examined in the initial analysis (i.e., the placebo condition
was excluded). The ensuing analysis was conducted using placebo and active drug conditions
with baseline excluded. (Note: a basic assumption of trend analysis is that “level” of
experimental conditions be of similar magnitude, which precludes simultaneous use of baseline
and placebo in the same analysis). The proportion of treatment variance (R2 trend) was computed
for each significant trend to determine the relative contribution of each trend component (e.g.,
linear, cubic, quadratic) when more than one component reaches statistical significance (Keppel,
1991).

Table 4: Trend Analysis for Symptoms Found in the Core Symptom Category
FLinear

R2Linear

FQuadratic

R2Quadratic FCubic

R2Cubic

Base-MPH

37.83**

0.15

20.77**

0.06

9.31*

0.00

Placebo-MPH

12.35*

0.05

2.36

0.01

2.05

0.01

Note. Base = baseline (no drug condition). MPH = methylphenidate. Base-MPH = trend analysis
using baseline and active methylphenidate conditions. PL-MPH = trend analysis using placebo
and active methylphenidate conditions. R2 = proportion of variance accounted for by trend
components. * = p < .05; ** = p < .001.
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Trend analysis of parent endorsement of physical and behavioral complaints excluding the
placebo condition (i.e., baseline, 5 mg, 10 mg, 15 mg, 20 mg) revealed significant linear [F (4,
256) = 37.83, p<.001], quadratic [F (4, 256) = 20.77, p<.001], and cubic [F (4, 256) = 9.31,
p<.001] trends. The linear trend accounted for the greatest proportion of variance (15%), whereas
6% and 3% of variance was accounted for by the two higher-order trends (see Table 4 for R2
values). This finding indicates that physical and behavioral complaints reported by parents that
mimic core/secondary features of the disorder evidence a moderately abrupt decrease between
baseline and MPH 5-mg, with minimal variation in frequency under higher dose conditions (see
Figure 1). Only the linear trend was significant for the placebo-active drug trend analysis [F (4,
256) = 12.35, p<.001], and the small proportion of variance accounted for (5%) indicates that the
primary change in complaint frequency results from changes between baseline and active drug
conditions.
Collectively, the preceding analysis indicates a significant reduction in parent reports of
physical and behavioral complaints that mimic core/secondary ADHD features under placebo
relative to baseline, and under active MPH conditions relative to both baseline and placebo, with
no significant variation in complaint frequency among active drug conditions. These findings are
consistent with the hypothesis that adult raters confuse some features of ADHD as related side
effects.
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Tier II Analysis: Preexisting /Normal Level Hypothesis
Parent and child reports of physical and behavioral complaints common to pediatric age
children were analyzed using a 2 (child and parents raters) x 6 (conditions: baseline, placebo, 5
mg, 10 mg, 15 mg, 20 mg) repeated measures analysis of variance (ANOVA) to examine the
preexisting/normal level hypothesis. This hypothesis posits that the myriad everyday physical
and behavioral complaints commonly reported by children (including those with ADHD) must
be accounted for by examining baseline frequency/severity rates to separate them from actual
treatment emergent symptoms associated with MPH.
The rater by drug condition interaction [F (5, 640) = 2.22, ns] and main effect for rater [F (1,
128) = 2.84, ns] were not significant, however, the main effect for drug condition was significant
[F (5, 640) = 4.42, p<.001]. The decrease in endorsements from baseline to placebo (p<.05) and
all active MPH conditions (all p-values <.05) is due primarily to decreased child endorsements
albeit insufficient to produce a rater main effect or interaction. Mean child and parent
endorsements of physical and behavioral complaints common to children under baseline,
placebo, and the four MPH conditions are depicted in Figure 2.
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Figure 2: Mean severity ratings parent and child endorsements of physical and behavioral
complaints commonly reported by children (including those with ADHD) in the general
population.
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Tier III Analysis: Side Effects Commonly Attributed to Psychostimulant Treatment
Parent and child reports of physical and behavioral complaints commonly attributed to
psychostimulant therapy (true emergent symptoms) were analyzed using a 2 (child and parents
raters) x 6 (conditions: baseline, placebo, 5 mg, 10 mg, 15 mg, 20 mg) repeated measures
analysis of variance (ANOVA). The rater by drug interaction [F (5, 640) = 2.94, p<.05] and main
effect for drug were significant [F (5, 640) = 10.66, p<.001]. There was no significant rater main
effect [F (1, 128) = .099, ns].
Post hoc analysis using Tukey’s HSD indicated that children endorsed significantly higher
severity rates of physical and behavioral complaints commonly attributed to psychostimulants
under baseline relative to placebo and all four active MPH conditions (all-p values < .05), and
under placebo relative to 5-mg, 15-mg, and 20-mg conditions (p<.05). No significant differences
emerged among the active MPH conditions. Parent endorsements showed a similar pattern of
results – significantly more physical and behavioral complaints were reported under baseline
relative to 5-mg and 20-mg MPH (all p-values<.05). No other contrasts were significant.
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Figure 3: Mean severity ratings of parent and child endorsements of physical and behavioral
complaints in the category of emergent symptoms commonly attributed to methylphenidate
therapy (true side effects).
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Collectively, these results indicate that the significant interaction effect was due to initially
higher child relative to adult complaint endorsements under baseline, coupled with lower
complaint severity under higher doses. Trend analysis results are summarized in Table 5 and
reveal that child ratings are best characterized by a linear decrease in physical and behavioral
complaints, with the largest decrease occurring between baseline and active medication
conditions. Parent ratings are best characterized by a cubic decrease in complaints that accounts
for less than 2% of change – indicating minimal change across the experimental conditions.

Table 5: Trend Analysis for Symptoms that are considered "Emergent" or True Side Effects of
Medication.
FLinear

R2Linear

FQuadratic R2Quadratic FCubic

R2Cubic

Base-MPH

26.82**

0.11

6.23*

0.03

8.94*

0.02

Placebo-MPH

6.25*

0.03

0.02

0.00

1.42

0.00

Child

Parent
Base-MPH

2.57

0.01

1.27

0.00

4.05*

0.02

Placebo-MPH

0.56

0.00

0.11

0.00

2.28

0.01

Note. Base = baseline (no drug condition). MPH = methylphenidate. Base-MPH = Trend analysis
using baseline and active methylphenidate conditions. PL-MPH = Trend analysis using placebo
and active methylphenidate conditions. R2 = proportion of variance accounted for by trend
components. * = p < .05; ** = p < .001.
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CHAPTER FIVE: CONCLUSION
The present study examined competing hypotheses that may help explain past reports of
paradoxical reductions in physical and behavioral complaints associated with MPH therapy in
children with ADHD. Symptoms on the STESS side effect rating scale were separated into
specific categories to investigate predictions that some physical and behavioral complaints
represent ADHD primary/secondary features, whereas others reflect non-medication related
complaints reported by children in general, or true emergent symptoms specific to
psychostimulant treatment.
Parent and child endorsements of physical and behavioral complaints showed significant
reductions from baseline to active MPH conditions for all three categories, and were of a
sufficient magnitude to be considered clinically meaningful (i.e., range = 27% to 62%).
Significant reductions in symptom endorsements were also observed between placebo and active
MPH conditions for parent ratings that reflect ADHD core/secondary features (e.g., sitting still,
difficult peer relationships), and for child symptom ratings specific to MPH treatment (e.g.,
stomachaches, reduced appetite). These changes were smaller in magnitude than those observed
for the baseline-MPH contrasts, and indicate that part of the observed effect is associated with
expectancy or other factors related to placebo phenomena. No significant differences emerged
among the four active MPH doses for child and parent endorsements across the three categories.
Our results are consistent with those reported in past studies that included baseline
measures of psychostimulant effects. For example, Ahman and colleagues (1993) reported
reduced frequencies in four behavioral symptoms assessed by the Stimulant Drug Side Effects
Rating Scale (Barkley, 2005) under their high dose MPH condition (dose range = .3 mg/kg to .6
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mg/kg). Efron, Jarman, and Barker (1997) reported similar results -- a decrease in frequency and
severity of “side effects” relative to baseline when comparing MPH to dexamphetamine at .3
mg/kg and .15 mg/kg, respectively. Placebo-controlled dose-response investigations without
baseline measures report similar findings (e.g., Firestone, et al., 1998; Fischer & Newby, 1991).
Collectively, these findings suggest that several items included on emergent rating scales likely
reflect behavioral phenotypical features of ADHD rather than true emergent symptoms related to
MPH therapy. Parent and teacher ratings of these scale items have previously been attributed to
“rater confusion,” however an equally plausible explanation is that raters are accurately
reflecting observed behavior changes in the children consistent with the vast literature on
psychostimulant response, and investigators have misinterpreted these ratings by relying on total
rather than item or factor scale scores. This holds even for scales developed specifically to
monitor emergent symptoms associated with psychostimulant therapy, such as the Stimulant
Drug Side Effects Rating Scale (Barkley, 2005), which contains multiple items that mirror core
and secondary features of ADHD (e.g., trouble sleeping, proneness to crying, daydreams).
Children’s complaints of physical discomfort on a weekly and reoccurring basis are well
documented in the literature (Eggers et al., 1999; DuPaul, et al., 1996; Mitchell et al., 1987). Our
results corroborate extant research in demonstrating that children with ADHD share this
propensity for experiencing weekly discomfort such as headaches, feeling tired, muscle aches,
stomachaches, and occasional dizziness under no-medication conditions. The results provide a
compelling rationale for recognizing that children, like adults, experience daily physical
discomfort that must be recognized and accounted for prior to initiating a medication trial. An
unexpected result, however, was the significant decrease in these complaints under placebo and
MPH conditions relative to baseline by child endorsements. Mean child complaint severity
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decreased 44% to 56% from baseline to active MPH conditions. A proportion of this change
appears to be related to expectancy effects associated with placebo phenomena in child ratings
(i.e., changes from baseline to placebo for child ratings was 52%). These effects are traditionally
attributed to a person’s belief in a treatment’s potential efficacy, but may also be mediated by
changes in emotional state, perception, and behavioral improvement (Stewart-Williams, 2004).
Placebo effects, however, only partially account for the significant reductions in complaints
from baseline to MPH. The additional reduction in children’s endorsements may reflect
improvement in associated areas of daily functioning, such as improved attention, academic
performance, and classroom conduct (e.g., DuPaul & Rapport, 1993; MTA Cooperative Group,
1999; Pelham et al., 1990). This explanation merits consideration and requires a carefully
designed protocol to determine whether improved behavioral and/or academic functioning serve
as significant mediators for children’s emergent symptoms.
Similar results were evidenced when examining child endorsement of symptoms highly
specific to psychostimulant medication. Children endorsed a significantly higher severity of
complaints for this category under baseline relative to placebo (a 34% decrease) and all four
active MPH conditions (decreases between 43% and 59%); and under placebo relative to 5-mg
(25% decrease), 15-mg (31% decrease), and 20-mg (38% decrease) conditions. Parent
endorsements showed fewer significant contrasts, with higher severity of physical and behavioral
complaints reported under baseline relative to 5-mg (28% decrease) and 20-mg (27% decrease)
MPH conditions only. Group-level analysis was supplemented by examination of individual
child rating scale results, and revealed moderate increases in select emergent symptoms for some
children (e.g., feeling sick to stomach, n = 11; skin itching, n = 11; dry mouth, n =8; less
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urination, n = 8; appetite reduction, n =7, and less bowel movements, n = 7) under the two
highest doses (i.e., 15-mg and 20-mg).
Although all three classes of potential emergent symptoms showed significant decreases
from baseline levels, several caveats merit consideration. Increased frequency and/or severity of
emergent symptoms reported by or observed in children receiving psychostimulant therapy are
probable to the extent that dosing regimens differ from the parameters reported herein,
particularly in the symptom category highly specific to MPH. That is, children receiving multiple
doses per day, single doses exceeding 20-mg, and over a longer duration of time are likely to
experience a higher frequency and/or severity of emergent symptoms (Gadow, 1986). Preschool
children with ADHD (Connor, 2002; Kollins, 2004), and those whose presentation includes other
clinical features such as developmental delays (Aman, Marks, Tubott, Wilsher, & Merry, 1991;
Handen et al., 1992), may also experience a higher frequency and/or severity of psychostimulant
related emergent symptoms. A final caveat involves the applicability of group-level results for
titrating and monitoring psychostimulant regimens for individual children. Generalization can
never be assumed, and is always limited owing to the highly idiosyncratic treatment response
observed within and across behavioral, cognitive, and emergent symptom domains in children
with ADHD (Rapport & Kelly, 1991).
Collectively, our findings point to a clear need to develop psychometrically sound
treatment emergent symptom rating scales for purposes of monitoring physical and behavioral
complaints in children treated with psychostimulants. Special care is warranted in wording scale
items to ensure that their content differentiates between emergent symptoms and core/secondary
symptoms of the disorder. This can be accomplished through extensive item refinement and
submitting items to expert judges for review (see Clark & Watson, 1995). The development of a
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separate factor scale that contains typical daily complaints endorsed by children based on extant
research may also be desirable. Separating these complaints from drug related emergent
symptoms affords practitioners improved ability to assess the extent of a child’s usual complaint
frequency and severity, and to determine whether they change with treatment as evidenced
herein. Inclusion of items that help differentiate improved attention from staring or constricted
attention are also desirable (for a discussion of over-focused phenomena associated with
psychostimulants, see Denny & Rapport, 2001). Finally, the administration of treatment
emergent scales prior to initiating therapy must be considered a de rigueur component of clinical
management for determining a true baseline picture of child complaints.
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